Here’s what you should know:
1. Ritter Pharmaceuticals is developing novel therapies that alter gut microbiome to treat gastrointestinal diseases. It is currently creating the first FDA-approved treatment for lactose intolerance.
2. Dr. Chey is a professor of gastroenterology at Ann Arbor-based University of Michigan.
3. He is on the board of directors for the American College of Gastroenterology as well as the Rome Foundation. He also serves on the International Foundation of Functional GI Disorders’ advisory board.
4. Dr. Chey is a past co-editor-in-chief for the American Journal of Gastroenterology.
5. Ritter Pharmaceuticals’ President Andrew Ritter said, “We are pleased to have the guidance and support from one of the leading and most respected experts in the field of gastroenterology.”
More articles on gastroenterology:
Former Surgery Partners CEO resigns from board & more — 8 ASC company key notes
5 tips to improve ASC implant payments
Driscoll Children’s Hospital raises $980k for new pediatric ICU, outpatient surgery center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
